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Abstract 
The sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) pump is responsible for pumping 
calcium from the cytosol back into the lumen of the sarcoplasmic reticulum post contraction. 
SERCA activity can be reduced by an inhibitory protein, phospholamban (PLN), which binds 
directly to the pump. Interestingly, overexpressing PLN in transgenic mice (PlnOE) creates a 
replica of centronuclear myopathy (CNM). CNM is a grouping of rare congenital diseases with 
three common muscular abnormalities: abundant central nuclei, centrally aggregated oxidative 
activity and type 1 fibre predominance.  Calcineurin (CnA) is a Ca2+-calmodulin dependent 
serine-threonine phosphatase, which is known to activate a signalling cascade leading to slow-
twitch fibre gene expression. Upon activation by excess Ca2+, CnA dephosphorylates nuclear 
factor of activated T-cells (NFAT) proteins, which then translocate to the nucleus where they 
act as transcription factors for slow-twitch fibre promotion. Western blotting of muscle lysates 
from PlnOE mice showed increased CnA and nuclear NFAT content in slow twitch muscle, 
soleus and gluteus minimus, while no differences were found in the diaphragm which contains 
much less CNM disease symptoms.  Therefore, this study examined the hypothesis that CnA 
activation may be driving the predominance of type I fibres and may be targeted as a potential 
therapeutic strategy to alleviate the CNM phenotype in PlnOE mice.  Here, developing (4 week 
old) and adult (4-6 month old) PlnOE mice were treated with the CnA inhibitor, cyclosporin A 
(CsA), at 25mg/kg body weight twice a day for two weeks. Soleus muscles from vehicle and 
CsA treated mice were excised for histology and immunofluorescence to assess the CNM 
phenotype, Western blotting for protein content and whole muscle contractility to assess muscle 
function. CsA treatment blunted type I fibre predominance and promoted hybrid and type II 
fibres in both age groups. CsA treated adult PlnOE mice were also found to have increased force, 
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decreased fibrosis, reduced PLN and sarcolipin content. CsA treatment did not eliminate central 
aggregations of oxidative activity or have an effect on the percentage of fibres displaying 
central nuclei suggesting these CNM features may not be connected to CnA activity.  CnA 
content was reduced in the CsA treated animals but changes in CnA activity in this study are 
unclear as western blotting showed increased activity while immunofluorescence displayed 
decreased activity and less nuclear NFAT. Surprisingly, CsA treatment had minimal effects in 
developing PlnOE mice with only small difference in fibre type observed between vehicle and 
CsA animals. In summary, CsA treatment provides modest improvements in fibre type, cellular 
phenotype and muscle function in adult PlnOE animals however it has little effect on younger 
mice developing the disease. Targeting fibre type as a potential treatment for CNM merits 
further research to determine the appropriate timing for treatment, other potential 
pharmaceuticals that do not disrupt immune signalling or hypertrophy and the underlying 
mechanism by which the overexpression of PLN causes CNM. 
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Introduction  
Calcium (Ca2+) is essential for the proper health, structure and function of skeletal muscle. 
In skeletal muscle, the sarcoplasmic reticulum (SR) is the main storage site for Ca2+,, where the 
Ca2+ concentration ([Ca2+]) has been measured to be 20mM (1) creating a large gradient between 
the SR lumen and the cytosol where [Ca2+] is approximately 30-100nM (2). Upon stimulation via 
an action potential, the dihydropyridine receptors (DHPR) located along the T-tubule membrane 
activate Ca2+ release from the SR by the opening of ryanodine receptors (RYR) embedded within 
the transverse portion of the SR membrane. When released into the cytosol, Ca2+ binds to 
troponin C allowing for cross bridge formation between actin and myosin and force generation 
(reviewed by Dulhenty, 2006). Upon cessation of the stimulus, subsequent re-uptake of Ca2+ 
back into the SR by the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pump initiates 
muscular relaxation. The cytosolic [Ca2+] at any time is critical to the proper function of a muscle 
cell and is tightly regulated.  Therefore, impairments in Ca2+ regulatory proteins such as DHPR, 
RYR, SERCA, and other Ca2+ buffering proteins and organelles including calsequestrin, 
parvalbumin, and mitochondria, could lead to dysregulated Ca2+ handling and decrements in 
muscle function and health.  In particular, much attention has been given to the role of SERCA 
dysfunction in several muscle diseases including Brody’s disease, cardiomyopathy, and 
Duchenne muscular dystrophy (DMD) (3-5). 
SERCA Pumps and Calcium Regulation 
The SERCA pump is a large 110kDa SR trans-membrane pump. There are three main 
isoforms of the pump, SERCA1, SERCA2, and SERCA3, each with alternative splicing variants, 
encoded for by the genes ATP2A1, ATP2A2 and ATP3A3, respectively (6, 7). Each SERCA 
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isoform and splice variant has a different expression pattern in tissues throughout the body; 
notable for this thesis are the splice variants SERCA1a expressed in fast glycolytic type II 
muscle and SERCA2a expressed in slow oxidative and cardiac muscles (7).  Although there are 
little differences in kinetics between the different SERCA isoforms in vitro (8), the level of 
isoform expression in vivo has a large impact on Ca2+ dynamics. Lytton et al. (1992) found that 
SERCA protein content was up to five fold higher in type II fibres compared to type I fibres in 
rat skeletal muscle (9). The increase in SERCA content in type II fibres corresponds with the 
finding that basal SERCA activity was nearly three fold higher in human type II fibres than type 
I fibres(10). Together the increased SERCA content and activity produce the faster muscular 
relaxation attributed with type II muscle fibres. 
Structurally, SERCA pumps can be broken down into four domains: 1) the A domain, 
also known as the actuator domain for Ca2+; 2) the N domain, which contains the nucleotide 
binding site for ATP; 3) the P domain or the phosphorylation domain, which contains the 351 
aspartate residue that becomes phosphorylated during SERCA’s catalytic cycle;, and 4) the M 
domain, which contains the ten transmembrane α-helices wherein lie the two Ca2+ binding sites 
(3, 11). As mentioned previously, the role of the SERCA pump is to actively transport Ca2+ from 
the cytosol back into the lumen of the SR and this is done through large conformational changes 
in the A, N, P and M domains driven by ATP hydrolysis.  Two major conformational states of 
SERCA have been identified: E1, in which, there is a high affinity for Ca2+ promoting ion 
binding within the cytosol, and E2, wherein a low affinity for Ca2+ allows for its dissociation into 
the SR lumen (12). Under optimal conditions, SERCA will load both Ca2+ binding sites and 
transport two Ca2+ ions per ATP hydrolyzed; however, there are several SERCA regulatory 
proteins, some of which may alter this optimal allosteric ratio.  
	   3	  
SERCA Regulation 
 Both positive and negative regulators of SERCA activity have been discovered, which 
work through varying mechanisms. The two most studied regulators of SERCA are the small 
integral proteins, sarcolipin (SLN) and phospholamban (PLN). SLN and PLN (31 and 52 amino 
acids, respectively) bind directly to the Ca2+ binding site within the M2, M4, M6 and M9 
transmembrane helices of SERCA (13, 14). When SLN or PLN are bound to SERCA, they 
inhibit SERCA activity by reducing its apparent affinity for Ca2+(15, 16). Furthermore in skeletal 
muscle, SLN but not PLN has been shown to uncouple the transport of Ca2+ from ATP 
hydrolysis meaning more ATP would be needed to transport the same amount of Ca2+ into the SR 
lumen (17, 18). Classically these inhibitory proteins have been associated with differing SERCA 
isoforms, with SLN and PLN binding and inhibiting SERCA1a and SERCA2a, respectively(16, 
19). However, recent evidence suggests the relationship between the differing SERCA isoforms 
and regulatory proteins may be more complex than originally hypothesized. Using human single 
fibre western blotting, Fajardo et al. (2013) found that although PLN may preferentially inhibit 
SERCA2a in type I fibres whereas SLN primarily inhibits SERCA1a in type II fibres, they have 
the ability to bind to both isoforms and are co-expressed in many fibres (20). This corresponds 
with previous research showing PLN and SLN have the ability to synergistically bind to a single 
SERCA pump causing super inhibition (21).   
Recently Anderson et al. (2015) discovered two additional SERCA regulatory proteins, 
myoregulin (MLN) and the micropeptide, DWORF. MLN is a homologous protein to SLN and 
PLN, which was discovered in a non-coding region of RNA. MLN was shown to be expressed in 
all skeletal muscle fibre types and, similar to PLN and SLN, has the ability to directly interact 
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with and inhibit SERCA (22).  DWORF, on the other hand, was shown to enhance SERCA 
activity by displacing inhibitor proteins such as SLN, PLN, and MLN(23). 
Cellular processes also have the capacity to affect SERCA function. While transient 
redox signaling has been shown to stabilize PLN in oligomer formations, which increases 
SERCA activity and improves cardriomyocyte contraction (24), cellular stress can cause 
irreversible oxidization, nitrosylation and S-glutathionyltion which negatively affect SERCA 
function (25). As well, oxidative damage has been associated with age-related reductions in 
cardiac muscle function as aged rat cardiac muscles contain similar SERCA content to healthy 
counterparts but have an increase in oxidative damage(26). In lieu of this, heat shock protein 70 
(HSP70), previously shown to be activated during oxidative stress, binds directly to SERCA, 
stabilizing the pump and maintaining SERCA function in the face of thermal stress (27), In 
accordance with this, HSP70 was also shown to be upregulated in DMD human biopsies, thought 
to be a compensatory mechanism to deal with the cytotoxic stress from the excessive 
intracellular Ca2+ associated with this myopathy(28).  
This connection between SERCA disfunction and disease states is not uncommon. DMD, 
cardiomyopathy/cardiac failure and aging have all been linked to decreased SERCA function, 
through decreased expression of the pump itself, increased expression of inhibitory proteins, or 
damage to the pump (26, 29, 30). As such, the manipulation of SERCA content or targeting of 
SERCA regulatory proteins has promise as a potential therapeutic strategy to combat muscle 
disease, such as DMD. Overexpression of SERCA1a in mdx mice, the murine model for DMD, 
caused a decrease in intracellular [Ca2+], reduced central nuclei counts and increased exercise 
capacity along with a reduction in other detrimental Ca2+ associated symptoms such as swollen 
mitochondria and calpain activation (31).   The overexpression of  heat shock protein 72 
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(HSP72) has also been shown to alleviate the mdx phenotype and improve contractility of 
diaphragm muscles via improved SERCA function(32). The effects of PLN on SERCA function 
have also been most extensively researched in cardiovascular health where its inhibition of 
SERCA2a in cardiac muscle has been associated with cardiomyopathy (33-35). Surprisingly, 
very little research has examined the role of PLN in skeletal muscle myopathy.  
Phospholamban 
 As stated previously, PLN inhibits SERCA activity by direct binding which lowers 
SERCA’s apparent affinity for Ca2+. Inherently, PLN is found in both a monomer and pentamer 
form, with monomer PLN being the active inhibitor of SERCA (36). The purpose of the 
pentamer formation of PLN is less clear and claimed to be both a selective cation channel (37) as 
well as a sink for phosphorylated inactive PLN(38). PLN has three distinct phosphorylation sites 
which are each phosphorylated by different kinases; protein kinase C (PKC) at Ser10, cAMP 
dependent protein kinase A (PKA) at Ser16 and Ca2+-calmodulin -dependent protein kinase 
(CaMKII) at Thr17 (39). Phosphorylation at any of these sites disassociates PLN from SERCA, 
relieves any inhibitory effects and in turn increases SERCA’s Ca2+ affinity and SR Ca2+ uptake 
(40). Likewise, ablation of PLN in mice increases SERCA activity causing decreased time to 
peak pressure and relaxation in the heart (41), a 2 fold increase in cardiomyocyte shortening 
upon contraction (42), and a 25% decrease in the time to half relaxation in soleus (43). 
Within cardiac muscle, the presence of PLN and its inhibition of SERCA2a activity is 
especially detrimental as excess cytosolic Ca2+ and delayed relaxation have been associated with 
reduced ventricular filling and stroke volume, as well as cardiac disease and heart failure (4). 
Correspondingly, phosphorylation of PLN has been shown to weaken its inhibition of SERCA2a 
(44), increasing the apparent Ca2+ affinity and enhancing relaxation during 𝛽-adrenergic 
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stimulation (45, 46).  As well, mutations in PLN cause cases of human dilated cardiomyopathy 
associated with refractory based heart failure (35). This pattern is also witnessed in mouse 
models as PLN overexpression in murine cardiac muscle causes cardiac hypertrophy and heart 
failure due to the inability to clear cytosolic Ca2+ (47, 48).  
Although there is evidence suggesting the relationship between inhibited Ca2+ cycling and 
myopathy exists in skeletal muscle as well, considerably less research has been done in contrast 
to cardiac muscle. Transgenic rabbits overexpressing PLN presented dystrophic features 
including extensive muscle wasting and fatty accumulation in slow twitch muscle fibres and 
were almost completely immobile by 6 months of age (49). A murine transgenic model, which 
overexpresses PLN (PlnOE) specifically in slow twitch fibreswas originally described by Song et 
al. (50).  Interestingly, this group found reduced contractility and muscle mass but reported no 
myopathic phenotype in these mice. In contrast, Fajardo et al. (2015) has since shown that this 
same transgenic model presents a drastic increase in SLN content, reduced SERCA activity and a 
severe myopathy phenotype most similar to centronuclear myopathy (CNM) (51).  
Centronuclear Myopathy 
 Centronuclear Myopathy, also known as myotubular myopathy, was first reported by 
Spiro et al. in a 1966 in a case study analysis of muscle tissue from an adolescent boy with 
muscle weakness and wasting (52). Upon histological analysis of muscle biopsies, three main 
pathological symptoms were found, which included: an abundance of central nuclei, a central 
aggregation of oxidative activity, and a predominance of type I fibers. Based on these three 
features, Spiro et al. speculated that the muscle looked as though it was arrested in development 
and hence chose to refer to it as myotubular myopathy. Since then, several genetic mutations 
have been uncovered and the etiology of CNM has strayed from the “arrested development” 
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theory, leading to the more common use of the term CNM over myotubular myopathy. 
Additionally, several other histological features have been associated with CNM, such as 
increased intracellular fibrosis, radiating SR strands upon SDH staining, triad deformations 
suggesting impairments in excitation-contraction coupling, and the presence of “Necklace fibers” 
which are small fibers containing centralized nuclei surrounded by a ring of mitochondria, 
sarcoplasmic reticulum and glycogen granules have also been reported (51, 53-55).  These 
additional features vary vastly depending on the genetic mutation origin and corresponding 
classification of CNM.  
 Typically, CNM is grouped into four classifications; autosomal recessive, autosomal 
dominant, X-linked recessive and sporadic random cases (56). The most common of the four 
types is X-linked recessive CNM, which is most often associated with a mutation in the 
myotubularin 1 (mtm1) gene within the X chromosome (57). As such, this form of CNM 
predominantly affects males with females only being a carrier of the mutation. The mtm1 gene 
codes for the protein myotubularin, a phosphoinositide phosphatase known to be essential in 
endosomal trafficking (58). Clinically, X-linked CNM displays the most severe variation of the 
disease commonly resulting in neonatal death (53, 59). The autosomal dominant form of CNM is 
associated with varying mutations along the gene coding for dynamin 2 (DNM2), a GTPase that 
forms around the necks of vesiculating membranes providing force for constriction as well as 
regulating actin and mictrotubule cytoskeletal networks (60).  Autosomal dominant CNM is 
characterized by a progressive phenotype with varying severity depending on the exact DNM2 
missense mutation (61-63). The autosomal- recessive and sporadic cases of CNM vary vastly in 
genetic abnormalities and clinical phenotypes. Mutations in hJUMPY (mtmr14), amphiphysin 
(bin1), and ryanodine receptor (ryr1) genes have all been linked to autosomal recessive and 
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sporadic cases (64-66). Sporadic and autosomal recessive cases of CNM are quite rare and are 
genetically classified on a case-to-case or family case basis. As a grouping, this category of 
CNM generally show a milder phenotype with onset occurring from neonatal to adulthood and a 
progressive muscular degeneration (67).   
Because of the variation in genetic mutations, CNM is heterozygous in respect to clinical 
presentation, cellular abnormalities and singling dysfunction. As such, there is not one clear 
mechanism behind the phenotype seen within this disease. Aside from the sporadic RYR1 
mutation case, all of the above genetic mutations encode for proteins involved in membrane 
trafficking and endo/exocytosis; however, the link between these mutations and how they work 
to cause the CNM phenotype is still unclear.  
 In order to conduct research into CNM, several transgenic animal models have been 
researched, including Bin1-null zebrafish, MTM1-mutated Labrador retriever dogs and mice, and 
microRNA133a-null mice (53, 68-70). Previous characterization of the PlnOE murine model of 
CNM by our lab revealed the three hallmarks of the disease previously mentioned as well as 
reduced muscle mass, contractile force and time to exhaustion, radiating SR strands and 
compensatory hypertrophy of type II fibres, and interestingly a significant upregulation of SLN 
(51). These CNM features correspond most closely with the autosomal dominant form of CNM. 
Consistent with this, soleus muscles from the PlnOE animals displayed increased Dnm2 levels, 
which is the genetically mutated protein in this form of human CNM. Murine models for this 
classification of CNM are lacking as the most common mutant variation, R465W Dnm2, display 
only impaired contractility and muscle atrophy with no central nuclei or type I fibre 
predominance (71). It is of importance to note that although there are no human cases of CNM 
associated with mutations in the gene for PLN, the PlnOE model seems to more closely replicate 
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autosomal dominant CNM than any other mouse model to date. As well, biopsies from patients 
with varying forms of CNM have shown a trending increase in the expression of both monomer 
and total PLN compared to healthy counterparts (51).  These findings, along with the sporadic 
cases of RYR1 mutations, suggest a link between Ca2+ dysregulation and the etiology of CNM 
which creates a new avenue to research potential therapeutic strategies as there is currently no 
treatment for CNM patients.  
Calcium and Calcineurin in CNM 
 One of the most characteristic aspects of CNM is the localization of the cellular 
symptoms to type I fibres. In the PlnOE model this phenomenon occurs due to the attachment of 
the PLN overexpression transgene to the MHCI promoter, however the clear mechanism that 
drives this phenomenon in human patients with CNM is yet to be uncovered. As can be seen in 
both the PlnOE model of CNM and human Dnm2-CNM muscles, type I fibres progressively 
atrophy, while type II fibres either show compensatory hypertrophy due to an increased 
workload or transition to type I fibres becoming susceptible to the CNM related damage(51, 61). 
These fibre type transitions and corresponding progression of the severity, may be due to 
calcineurin (CnA), a serine-threonine phosphatase that is known to initiate a calcium-dependent 
signaling cascade leading to the promotion of type I or slow-twitch fibre gene expression (72). 
Increases in cytosolic Ca2+ activate CnA by creating a complex with calmodulin, which binds to 
the catalytic subunit of CnA and disrupts its autoinhibition (73). Once active, CnA 
dephosphorylates nuclear factor of activated T-cells (NFAT) proteins, which are a family of 
transcription factors containing five isoforms (NFATc1-4 and NFAT5) (74). Under normal 
physiological conditions, NFATs are heavily phosphorylated and located in the cytoplasm with 
expression in a variety of cell types. Upon desphosphorylation via CnA, a nuclear localization 
	  10	  
signal is uncovered and NFATs translocate to the nucleus where they act as transcription factors 
(75, 76). Activated CnA and dephosphorylation of NFAT are part of a signaling pathway that has 
been shown to participate in a range of cellular adaptation processes, including immune cell 
activation (76), myoblast recruitment (77), myotube differentiation (78), and slow-twitch fibre 
type selection (79). With respect to fibre type selection, activated CnA alone has been shown to 
be sufficient to promote slow twitch fibre shift in transgenic mice (80). As well, McCullagh et al. 
(2004) demonstrated that overexpression of active NFATc1 stimulates the expression of MHCI 
and represses both MHCIIX and MHCIIB in rat muscle in vivo (81). Correspondingly, NFATc1 
has also been linked to the expression of other slow-twitch fibre type characteristics including 
myoglobin, and troponin I, further linking this specific NFAT isoform with the oxidative, type I 
muscle fibre profile (82, 83). 
Preliminary analyses conducted for this thesis and later published in Brain and Behavior 
(84), strove to assess whether the CnA-NFAT pathway was over-activated in the PlnOE model of 
CNM. Western blotting for CnA content showed a significant increase in the expression of CnA 
within slow twitch muscle, such as soleus and gluteus minimus of 4-6 month old PlnOE mice 
compared to wild type (WT) counterparts. Interestingly, this elevation in CnA content was not 
seen in the PlnOE diaphragm muscles, which present with the reduced type I fibre predominance 
and the milder CNM phenotype at a cellular level. In accordance with this, a significant increase 
in nuclear NFAT content was found in PlnOE gluteus minimus and a trending increase in PlnOE 
soleus. Again there was no difference in nuclear NFAT levels in diaphragm between PlnOE and 
WT animals. Together these data indicate the CnA-NFAT pathway is over activated in adult 
PlnOE slow twitch muscles and presenting a possible therapeutic target in this model.   
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This thesis aimed to determine whether blocking the fibre type shift in PlnOE muscles, via 
the administration of a well-known CnA inhibitor, cyclosporin A (CsA), would alleviate the 
disease phenotype and restore or retain muscle function in this model. Due to the progressive 
nature of this disease and cellular phenotype, we assessed the use of CsA as a potential 
therapeutic treatment in mice aged 4-6 months with fully developed CNM characteristics and 
developing, 4-6 week old mice with a milder phenotype. CsA has been previously researched as 
a method to alter fibre type profiles.  A dose of 250nM CsA almost entirely attenuated the shift 
to slow MHC expression seen with spontaneous contraction in cultured rat myotubes along with 
an increase in fast MHC expression (85). As well, the same 50mg/kg body weight/day dosage of 
CsA as used in this thesis, has previously been shown to halt the shift towards type I fibres in 
plantaris muscles during hind limb overload of wild type mice (86). CsA does have alternative 
functions which could have deleterious or beneficial affects, including: binding to cyclophiin and 
preventing the opening of the mitochondrial permeability pore(87) as well as being commonly 
used as an immunosuppressant in humans(88).  
Conceptually, within the PlnOE model, reducing the amount of type I fibres via CsA 
administration, would lead to an improved phenotype not only because the CNM disease 
characteristics are predominantly localized in type I fibres but also because PLN overexpression 
occurs specifically within type I fibres in this model. Although fibre type specific genetic 
mutations do not occur in human CNM cases, it is possible that, if successful, this strategy may 
be useful in other animal models of CNM and human CNM where type I fibre predominance, 
atrophy and cololaization of CNM characteristics with type I fibres are also present.  
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Statement of the Problem  
 To date, there is no treatment option for patients with CNM. As the presence of atrophied 
type I fibres that predominantly display the other CNM disease characteristics is a feature shared 
by all classifications of CNM, it is imperative to examine the potential pathways which may 
drive this phenomenon. This thesis examined the effects of CsA administration and reduced CnA 
activity in PlnOE mice as a potential therapeutic strategy to prevent type I fibre predominance and 
alleviate the CNM phenotype in this model. Developing (4-6 week old) and adult (4-6 month 
old) PlnOE animals were used in this study to determine whether CsA treatment is more effective 
in halting the progression or in reversing the CNM phenotype associated with the PlnOE model.  
Objectives  
 The objectives for this thesis were as follows: 
1. To examine whether CsA treatment could prevent or reverse type I fibre predominance in 
muscles from PlnOE mice. 
2. To examine whether CsA treatment can reduce the other markers of CNM in muscles 
from PlnOE mice, including:  centrally located nuclei, central aggregation of oxidative 
activity, and fibrosis. 
3. To examine the effects of CsA treatment on SERCA activity and the SERCA regulatory 
proteins, PLN and SLN 
4. To examine whether CsA treatment will increase strength and muscle function in PlnOE 
mice. 
5. To examine whether CsA is a viable treatment for both developing (4-6 week old) PlnOE 
mice and adult (4-6 month old) PlnOE mice. 
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Hypothesis 
The hypotheses in relation to these objectives listed above: 
1. CsA treatment would decrease CnA expression and activity, increasing 
phosphorylated NFAT and preventing the transition towards type I fibres seen in PlnOE 
mice in both age groups.  
2. Any decrease in type I fibres from CsA treatment would also reduce the other CNM 
features; including central nuclei, muscle atrophy and central aggregation of oxidative 
enzymes and activity, and fibrosis  
3. In accordance with fibre type, PLN and SLN content would be reduced in CsA treated 
muscles compared to vehicle in both age groups. As a result, SERCA activity would 
also be increased in CsA treated solei. 
4. CsA treatment would increase muscle function as seen by an increase in force and 
contraction and relaxation dynamics as a result of both the decrease in the CNM 
phenotype and the decrease in PLN and SLN.  
5.  CsA treatment would be more apt to prevent the formation of CNM in the younger 
age group than to reverse the damage and phenotype seen in the adult age group.  
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Methods 
Transgenic Mice 
Transgenic mice were originally generated by Song et al. (50). Briefly, the PLN coding 
and cDNA regions were ligated into the β-MHC promoter. This transgene was then injected into 
fertilized mouse eggs and transgenic mice overexpressing PLN in their type I muscle fibres were 
developed. These commercially available mice were then purchased (000067-MU, Mutant 
Mouse Regional Resource Centre, Columbia, MO) to generate a colony at the University of 
Waterloo. In maintenance of this colony, animals were bred male heterozygous for the PlnOE 
transgene to female wild type as we found a severe phenotype in homozygous mice that posed 
problems for examining mechanisms and potential therapies. To assess genotype, littermate 
animals were ear notched and the DNA samples were digested using pureLink Genomic DNA 
mini kit (Invitrogen, Carslbad, CA) and amplified through a polymerase chain reaction (PCR) 
method to delineate whether an animal was wild type or PLN overexpressing. Further details on 
the genotypeing protocol used can be found in the appendix. All animals were caged with 
littermates and given food and water ad libitum. For the duration of the study animals were 
housed in an environmentally controlled room on a 12:12hr light-dark cycle. All experiments 
were reviewed and approved by the University of Waterloo Animal Care Committee in 
accordance with the Canadian Council on Animal Care. The below treatments and assessments 
were conducted on mice in two age groups: developing (4-6 weeks) and adult (4-6 months). 
Ages were chosen according to previously mentioned research done by Fajardo et al (2015) on 
the progression of fibre type shifts in PlnOE mice (51). 	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Cyclosporin A  
Cyclosporin A was dissolved in a 50% DMSO and saline solution as per its hydrophobic 
nature at a concentration of 2.5mg/ml. A vehicle solution of DMSO and saline was also prepared 
in the same volume. Drug and vehicle preparation were made the evening before injection and 
stored at -20°C. PlnOE mice were injected subcutaneously with 25mg/kg body weight of CsA or 
the equivalent volume of the vehicle twice a day for two weeks. Mice were weighed daily to 
capture any changes in body weight over the course of injections both to determine drug or 
vehicle dosage and any potential drops in weight associated with stress. At the end of the two 
weeks, mice were sacrificed for dissection and tissue collection.   
Whole Muscle Contractility 
After cervical dislocation, intact solei from PlnOE mice were dissected and placed in an 
oxygenated bath (95% O2, 5% CO2) with Tyrode solution containing 121mM NaCl2, 5mM KCl, 
24mM NaHCO3, 1.8mM CaCl2, 0.4mM NaH2PO4, 5.5mM glucose, 0.1mM EDTA, and 0.5mM 
MgCl2, pH 7.3, which was maintained at 25°C. The muscles were mounted between two 
platinum electrodes and force was electrically induced from 1 to 100Hz using a biphasic 
stimulator (Model 710B, Aurora Scientific, Inc.) Once the stimulation protocol was complete the 
muscle was removed from the bath, de-tendonized and weighed to allow for normalization of 
data. Peak isometric force across all frequencies of stimulation, and maximal rates of contraction 
and relaxation were recorded, normalized to cross sectional area and analyzed on Excel.  
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Histological, Histochemical and Immunofluorescence Staining 
Soleus muscles were excised and mounted in O.C.T. compound cooled in isopentane 
before freezing in liquid nitrogen. Samples were then cut into 10μm thick sections and mounted 
to Vectabonded slides in a -20°C cryostat (Thermo Electronic).  Histological staining with 
Hematoxylin and Eosin (H&E) was conducted to assess central nuclei counts.  Percent central 
nuclei values were calculated by dividing the total number of fibres displaying central nuclei by 
the total fibre number for the entire section. Van Gieson staining f was performed to assess 
intramuscular fibrosis. Once stained, full section images were converted to greyscale in order to 
set a threshold for background staining and then fibrosis was calculated with ImageJ. 
Histochemical staining included succinate dehydrogenase (SDH) to assess oxidative activity and 
localization. A brightfield Nikon microscope linked to a PixeLink digital camera was used to 
acquire images of the stained sections and ImageJ software was used to analyze the images. 
Immunofluorescent staining was done for fibre type and NFAT assessments. Fibre typing was 
done as previously described (89) to determine muscle fiber type using primary antibodies from 
Developmental Studies Hybridoma Bank against the differing myosin heavy chain (MHC) 
isoforms: MHCI	  (BA-F8), MHCIIa (SC-71) , MHCIIb (BF-F3) . An Axio Observer Z1 
fluorescent microscope was used to capture images of the slides and ImageJ was used to 
determine fiber type distribution and cross sectional area. Immunoflourescent staining for NFAT 
was conducted as per the protocol in the appendix. Quantification of colocalization between the 
NFAT and DAPI channels were conducted on whole sections and background was removed as 
previously discussed for fibrosis. Quantification of colocalization was completed using the 
Colocalization Colourmap plugin for ImageJ.  
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Colocalization Colourmap uses the following equation: 
𝑛𝑀𝐷𝑃𝑥,𝑦 = 𝐼𝑎 − 𝐼𝑎 𝐼𝑏 − 𝐼𝑏(𝐼𝑎!"# − 𝐼𝑎)(𝐼𝑏!"# − 𝐼𝑏) 
where 𝐼𝑎 and 𝐼𝑏 denote the intensity of a given pixel in images a and b, 𝐼𝑎 and 𝐼𝑏 represent 
average intensities for their corresponding images and 𝐼𝑎!"#  and 𝐼𝑏!"# are the highest pixel 
intensity in each image. This equation is used to assess the channel images from DAPI and 
NFAT staining and results in an index of correlation for two images, where a value of 0 
corresponds with no colocalization and a value of one indicating full colocalization of the two 
channels.  
Western Blotting  
Western blotting was done for the following proteins: CnA, PLN, SLN, NFAT and 
Phospho-NFAT. Briefly, soleus sample was prepared with Laemeli buffer and loaded into SDS-
polyacrylamide gels and ran electrophoretically for 75 min between 100 and 120V. Proteins were 
then transferred to a polyvinylidene difluoride (CnA, PLN, NFAT and p-NFAT) or a 
nitrocellulose (SLN) membrane on ice via wet transfer at 100V for 60mins (CnA, PLN, SLN) or 
for 45 minutes at 23V using semi-dry transfer methods (NFAT/p-NFAT). Membranes were then 
blocked in 5% milk in TBST (CnA, NFAT), signal enhancer (PLN) or BSA (p-NFAT, SLN) for 
one hour, after which primary antibodies were applied in varying concentrations in the 
corresponding blocking agent for one hour or overnight. Membranes were washed in TBST (3 
times for 5 minutes) before and after an hour incubation in the corresponding HRP conjugated 
secondary antibody and Streptactin. After the final wash, chemiluminescence agents were 
applied to the membrane for detection and GeneTools (Syngene, MD, USA) was used to image 
and analyze the optical densities. A comprehensive list of details for all primary antibodies 
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information and dilution as well as protein load for each protein of interest can be found in the 
appendix.  
 
Ca2+ ATPase activity 
The Ca2+ ATPase assay as previously described by Duhamel et al. (2007) was done to 
assess SERCA activity in soleus homogenates of CsA and Veh treated PlnOE mice (90). Ca2+ -
dependent SERCA activity was measured at Ca2+ concentrations ranging from pCa 7.0 to 4.5 
using a plate reader assay on a spectrophotometer. GraphPad Prism was used to generate activity 
curves by non-linear regression curve fitting using a general sigmoidal model for substrate 
activity. SERCA activity was measured in the presence of Ca2+ ionophore A23187 (Sigma 
C7522) in order to reduce any back inhibition due to SR vesicle filling. 
 
Statistical Analysis 
 All results are presented as means ± standard error of the mean (SEM). Unless otherwise 
stated, all statistical analyses were done using a two-way ANOVA to compare between treatment 
and age groups. Statistical significance was established at p<0.05. Graph Pad Prism Statistical 
Software was used for all statistical analyses and final image generation. 
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Results 
Animal Physical Characteristics 
 Developing, 4-6 week old, and adult, 4-6 months old, PlnOE animals were treated with 
either 25mg per kg body weight of CsA or the corresponding volume of vehicle (DMSO and 
saline) twice a day for two weeks. There was no significant difference between the change in 
body weight during injections between adult PlnOE animals treated with CsA or vehicle. As 
expected, developing animals gained weight during the injection period, however similar to the 
adult groups there was no significant difference in delta body weight between CsA and vehicle 
treatments.  Soleus to body weight ratios also did not change between animals treated with CsA 
or the corresponding dose of vehicle, regardless of age. However, there was a main effect of age 
for both delta body weight and soleus to body weight ratios meaning the 4-6 week old animals 
gained more body weight during injections and had larger soleus muscle for their size than the 4-
6 month old animals, regardless of treatment.  
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Figure 1. Delta Body Weight and Soleus: Body Weight of PlnOE animals treated with CsA vs. 
Vehicle. Changes in body weight of PlnOE animals post treatment with CsA or vehicle (A). Soleus 
weight (mg) normalized to total body weight (g) of CsA and vehicle treated PlnOE animals (B).  n=7  
for 4-6 months and n= 3 for 4-6 weeks. * main effect of age. P ≤ 0.05 
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Muscle Fibre Type and Cross Sectional Area 
Fibre type distribution was assessed through immunofluorescence for MHC isoform 
(Fig. 3A) and analyzed using planned comparisons between treatments for each MHC isoform 
in both age groups. CsA treatment caused an approximate 10% reduction in the percentage of 
type I fibres in the soleus muscles from both 4-6 week old (p=0.04, Fig. 3B) and 4-6 month old 
(p=0.03, Fig. 3B) PlnOE mice. In accordance with this, both age groups had a shift towards type 
IIA fibres, increases of 6% and 7% in developing animals (p=0.04, Fig.3A) and adult animals 
(p=0.05, Fig. 3A), respectively. However it is important to note that this treatment did not fully 
restore fibre type percentages back to wild type levels, which have been previously recorded at 
45% type I and type IIA and 10% type IIB for wild type mice from this colony (51). Cross 
sectional area was assessed using a two way ANOVA to compare the effects of age and 
treatment on PlnOE mice. There were no significant differences in the cross sectional area of 
type I fibres with CsA treatment in developing or adult mice (Fig. 3C). However, there was a 
significant main effect of age on the cross sectional area of type IIA fibres, with adult PlnOE 
mice presenting larger type IIA fibres than the younger animals, regardless of treatment 
(p=0.01, Fig. 3C).   
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Figure 2. Fibre Type Changes in CsA treated PlnOE soleus compared to Vehicle treated. 
Representative fibre type immunofluorescent images of soleus sections from 4-6 week and 4-6 
month old animals treated with CsA or vehicle (A). Type I fibres are presented in blue and type IIa 
in green. Fibre type distributions (B) and cross sectional area (C) of individual fibre types were 
quantified from developing and adult PlnOE mice treated with CsA or vehicle. n = 7 vs 6 for adult 
and n= 6 for developing. * significantly different from vehicle treated. ** main effect of age  
P ≤ 0.05 
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Centronuclear Myopathy Features 
It was hypothesized that blocking CnA activity and reducing the type I fibre 
predominance would result in a corresponding reduction in the presence of the other two 
disease features, namely abundant central nuclei and central aggregation of oxidative activity. 
However, although CsA treatment did decrease type I fibre predominance, there were no 
differences between CsA and vehicle in the presence of central nuclei across age groups. There 
was a main effect of age, with older 4-6 month animals displaying increased central nuclei 
regardless of treatment (p=0.02, Fig 3B). 
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Figure 3. Central Nuclei Counts in PlnOE soleus muscles treated with CsA or vehicle. 
Hematoxylin and Eosin staining was conducted on the soleus muscle of animals treated with CsA 
or vehicle at 4-6 weeks and 4-6 months of age (A). Quantification of total central nuclei counts was 
then done using Image J software (B). n=6 vs. 7 at both age groups. All scale bars are 100μm 
**main effect of age. P ≤ 0.05 
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As can be seen in Figure 4 and in accordance with central nuclei percentages, SDH 
staining revealed that the presence of dense bodies in the interior of the fibre persisted in CsA 
treated soleus muscle cross sections, denoting the central aggregation of oxidative activity. 
Although these dense, centrally located SDH staining persisted in both age groups, as of yet, 
there has been no successful way to quantify the presence of this phenomenon so it is unclear as 
to whether the occurrence of this CNM characteristic was altered with CsA treatment.  
  
Figure 4. Abnormalities in SDH staining in PlnOE animals regardless of treatment. Representative 
images of Succinate Dehydrogenase staining completed on soleus cross sections of PlnOE animals 
treated with either CsA or vehicle at 4-6 weeks or 4-6 months of age. All scale bars are 100μm 
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Van Geison staining was done to assess the level of intracellular fibrosis in soleus 
muscles of PlnOE animals treated with CsA and vehicle.  A significant interaction effect was 
found, with younger 4-6 week old mice presenting less fibrosis than the adult 4-6 month old 
animals (p<0.0001, Fig. 5B) and CsA treated mice having significantly less fibrosis than their 
vehicle treated counterparts (p=0.001, Fig. B). Post hoc analysis also revealed a significant 
difference in the percentage of fibrosis between the 4-6 month old vehicle treated animals and all 
other groups.  
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Figure 5. Effects of CsA and Vehicle treatment on Fibrosis of PLNOE Soleus.  
Representative images of Van Geison staining between CsA treated and vehicle treated 
animals 4-6 weeks (n=4) and 4-6 months old (n=3) (A). Quantification of intracellular 
fibrosis (B). * significantly different from all other groups. A significant interaction effect 
between age and treatment was found for fibrosis. P ≤ 0.05 
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Phospholamban and Sarcolipin 
As expected, Western blotting showed a drop in the expression of PLN in the soleus of 
CsA treated animals compared to vehicle treated muscles at 4-6 months of age (p=0.03, Fig. 7E). 
As well, the same membrane was analyzed for pentamer PLN revealing a slight but non-
significant increase in the inactive pentamer PLN in the CsA treated soleus compared to the 
vehicle treated muscle (p=0.32, Fig. 6F). When assessed in relation to one another, there was a 
significant reduction in the monomer to pentamer PLN ratio which indicates a reduction in the 
inhibitory function of PLN overall (0.03, Fig. 6G). In the younger, 4-6 week old PlnOE mice 
treated with CsA there was no significant differences between monomer (p= 0.97, Fig. 6A) or 
pentamer PLN (p=0.30, Fig. 6B) and this corresponded with no change in the monomer to 
pentamer PLN ratio (p=0.60, Fig. 6C) between CsA and vehicle treated animals at this age.  It 
should be noted, however, that there is still an overexpression of PLN in the treated animals at 
both age groups as monomer PLN in WT animals cannot be detected at this low protein load 
(2.5ug) (51). 
As stated previously, there is a significant upregulation of SLN content in soleus muscles 
from PlnOE mice, which could worsen the myopathy phenotype as SLN and PLN have been 
shown to cooperatively bind to SERCA causing super-inhibition of the pump. With CsA 
treatment there was a trending decrease in the SLN content in the soleus muscle of 4-6 month old 
animals compared to vehicle treated animals (p=0.10, Fig. 7H). As with nearly all the other 
findings thus far, no significant differences were found between SLN content with CsA treatment 
in the 4-6 week old animals (p= 0.18, Fig 6D).  
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Figure 6. Phospholamban and Sarcolipin expression in CNM soleus treated with Vehicle or CsA. 
Western blotting for monomer (A&E) and pentamer (B&F) PLN and SLN (D&H) was conducted 
soleus homogenates of developing and adult PlnOE mice treated with CsA or vehicle. Monomer to 
pentamer ratio was derived by dividing monomer density by pentamer density before normalizing 
(C&G). Optical densities were normalized to actin or ponceau depending on protein load. * 
significantly different than vehicle treated using standard student’s t-test . n= 6 vs 7. P= 0.05  	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Whole Muscle Contractility  
Whole soleus muscles were excised from CsA and vehicle treated PlnOE mice and 
stimulated ex-vivo. Planned comparisons at each stimulation from 1-100Hz were done to assess 
muscle contractility between treatment groups. The solei of CsA-treated 4-6 month old PlnOE 
mice displayed increased force per cross sectional area at all frequencies, with significance at 
twitch (p=0.02, Fig. 7E) and at the higher frequencies from 70Hz to 100Hz (p<0.05, Fig. 7E). 
This effect was not seen between the vehicle and CsA treated 4-6 week old animals (Fig. 7A). 
Maximal twitch and tetanic force for both vehicle and CsA treated developing and adult mice are 
shown in Figures 7B&F and 7C&G, respectively. Two way ANOVA analysis revealed no 
significant main effects for treatment or age for maximal twitch force, however there was a 
significant increase in twitch force per cross sectional area of CsA treated soleus versus vehicle 
treated of 4-6 month old animals (p=0.05, Fig. 7B). At maximal tetanic force there was a main 
effect of treatment, with CsA treated animals having increased force regardless of age (p=0.05, 
Fig. 7F). Although there was not an interaction effect between age and treatment, planned 
comparison analyses showed a significant increase in the maximal tetanic force of 4-6 month old 
CsA treated animals compared to all other groups (p≤0.02, Fig. 7F).   
Interestingly, there was no difference in rate of relaxation between vehicle and CsA 
treated solei during twitch stimulus for either age group (Fig 7C). However, when stimulated at 
100Hz creating a tetanic contraction, there was a main effect of age with the solei of 4-6 month 
old animals relaxing slower in both treatment groups (p=0.03, Fig. 7G). Similarly, treatment had 
no significant effect on the rate of contraction at any age but there was a significant decrease in 
the rate of contraction in 4-6 month old animals compared to 4-6 week old animals across 
treatment groups (p=0.02, Fig. 7H). 
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Figure 7. Force Analysis between CsA-treated and Vehicle PlnOE animals at 4-6 Months 
and 4-6 Weeks. Force per cross sectional area frequency curve for soleus muscles from PlnOE 
animals aged 4-6 weeks (A) and 4-6 months (E). Single twitch force (B) and 100Hz tetanic 
force (F) per cross sectional area for PlnOE mice. Rates of relaxation between CsA and vehicle 
treated developing and adult PlnOE animals for twitch (C) and 100Hz tetanic (G) contractions. 
* significantly different from adult CsA treated.  ** main effect of age. n =6 vs 7. P ≤ 0.05 	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Ca2+	  ATPase	  Activity 	   As all of the previous data have shown CsA administration only improves the CNM 
phenotype and muscle function of adult, 4-6 month old PlnOE animals, SERCA activity was 
assessed in the soleus muscles of the adult CsA treated animals and their vehicle treated 
counterparts. Surprisingly, there was no significant difference in the maximal SERCA activity 
(Vmax) (p=0.94), or the KCa (p=0.98), denoting the pCa required to elicit half maximal SERCA 
activity, in CsA verses vehicle treated soleus muscle (Fig. 8). 	  
  
4.55.05.56.06.57.0
0
50
100
150
200
250
pCa
A
TP
as
e 
A
ct
iv
ity
(µ
m
ol
/m
in
/g
)
SERCA Activity
Vehicle
CsA Treated
Vmax KCa
VEH 220.3 ±  52.57 5.78
CSA 226.0 ± 52.08 5.79
Figure 8. SERCA Activity in the soleus muscle of 4-6 Month Old PlnOE mice Treated with CsA 
or Vehicle. Ca2+ -ATPase activity -pCa curves for soleus homogenates from CsA (n=3) and vehicle 
(n=4) treated PlnOE mice. Values for Vmax and KCa are listed as mean ± standard error of means. * 
significantly different from vehicle treated using standard student’s t-test. P ≤ 0.05 
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Calcineurin and NFAT expression 
 After administration of CsA for two weeks, there was a significant decrease in the 
expression of CnA within the soleus muscles of adult mice compared to their vehicle treated 
littermate counterparts (p=0.05, Fig. 9A). However, Western blotting showed no change in total 
NFATc1 content (p=0.83, Fig. 9B) but a significant reduction in phosphorylated NFATc1 
(p=0.04, Fig. 9C) in treated soleus muscles compared to vehicle treated animals. When 
comparing NFAT-p to total NFAT, which should indicate the localization of NFAT, there was a 
significant decrease in the ratio of CsA treated soleus compared to vehicle treated suggesting 
increased nuclear localization of NFAT with treatment (p=0.01, Fig. 9D). This is in direct 
contradiction to the fibre type assessment and PLN content previously shown which would 
suggest lower CnA activity and reduced NFAT translocation to the nucleus. 
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Figure 9. Calcineurin Content and NFAT localization in CsA and vehicle treated PlnOE animals.  
Western blotting for CnA (A), NFAT (B), and NFAT-p (D) content in soleus samples from CsA or 
vehicle treated PlnOE animals aged 4-6 months. NFAT-p content in relation to total NFAT content (C). 
All blots were normalized to total protein via ponceau stain. n=6 vs 7. * significantly different from 
vehicle treated using standard student’s t-test.  P ≤ 0.05 
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In an attempt to clarify this discrepancy, immunofluorescence for NFATc1, along with 
DAPI and dystrophin for nuclei and the plasma membrane respectively, was conducted on serial 
cross-sections of soleus muscles from CsA and vehicle treated animals at both age groups. To 
quantify the colocalization of DAPI and NFAT, the statistical model adapted by Jaskoski et al. 
(91) was used. This model computes the correlation between a single pixel on two different 
channel images while maintaining the x and y coordinates which results in a correlation index 
where zero is equivalent to no correlation and one corresponds with total overlap of the two 
fluorescent signals of interest. Using this method, there was a significant main effect of 
treatment, with CsA treated animals displaying a significant decrease in the colocalization of 
NFAT and DAPI fluorescence compared to vehicle counterparts across age groups (p=0.03, Fig. 
10C). Although there was not an interaction effect between age and treatment, planned 
comparisons show vehicle treated 4-6 month old animals showed significantly more NFAT and 
DAPI colocalization than all other groups including: their age matched CsA treated littermates 
(p=0.03) as well as both CsA (p=0.01) and vehicle treated (p=0.04) developing animals (Fig. 
10C). These data corroborate with the fibre type shift and the reduction in the expression of PLN 
in adult but not developing PlnOE mice, to suggest CsA administration decreased CnA activity 
and nuclear NFAT content in 4-6 month old animals and caused no difference in 4-6 week old 
animals.    
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Figure 10. NFAT colocalization with Nuclei in CNM Soleus Treated with CsA or Vehicle. 
Representative images of immunofluorescence for NFAT (green), DAPI (blue) and Dystophin (red) 
along with colocalization images of NFAT and DAPI from CsA and vehicle treated PlnOE mice aged 
4-6 weeks (A) and 4-6 months (B). Quantification of the colocalization of NFAT and DAPI. * 
significantly different from all other groups. ** main effect of treatment. P ≤ 0.05 
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Discussion  
The primary goal of this research was to examine whether pharmacological inhibition of 
CnA using CsA is an effective therapeutic strategy to alleviate CNM and improve skeletal 
muscle function in PlnOE mice. As hypothesized, a two-week dosage of 50mg/kg body 
weight/day of CsA administered to PlnOE mice resulted in a significant reduction in the 
predominance of type I fibres and increased hybrid and type IIA fibres in both 4-6 week and 4-6 
month old age groups. These fibre type transitions suggest that CsA treatment was successful in 
blocking the dephosphorylation of NFAT by CnA and the promotion of MHCI transcription. 
However, this is a modest reduction as the CsA treated PlnOE solei were still 35% above what is 
expected of a wild type animal of this background (51). With the exception of one other study by 
Michel et al. (2007), who reported that the same dosage of CsA completely prevented the shift 
towards type I fibres in surgically overloaded plantaris muscles from CD-1 male mice (92), there 
is no other study in the literature to compare our results with. The effects of CsA on muscle fibre 
type observed in this study are not even really comparable with the study by Michel et al., as the 
models examined are very different.  
Unexpectedly, there were no significant differences in the cross sectional area of specific 
fibre types between treatment groups in this study. There is contradictory evidence as to whether 
CnA activity is essential for the promotion of muscle hypertrophy either through activating the 
Akt/mTOR pathway, regulating myostatin expression, or interacting with MEF2 (93, 94). Michel 
et al. have suggested that hypertrophy is blunted with high dosages of CsA such as the one used 
in this study. However, 4-6 month old PlnOE mice had significantly larger type IIA fibres across 
treatment groups, which could suggest hypertrophy was not blocked during the CsA treatment or 
that previous compensatory hypertrophy was maintained during treatment.  Additionally in this 
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study, any potential increase in the cross sectional area of type II fibres may be masked by the 
variance introduced as smaller atrophied type I fibres transition towards type II. 
One possible explanation for the fairly modest effects of CsA treatment on muscle fibre 
type and size in PlnOE mice could also be a low treatment efficacy and less inhibition of CnA 
than expected. In this regard, the results are mixed for measures of CnA activity and for the 
different age groups examined in this study.  In adult 4-6 month old animals, 
immunofluorescence analyses show that CsA treatment resulted in a decrease in the 
colocalization of NFATc1 and DAPI fluorescence, indicating that CsA treatment was successful 
in blocking the CnA- dependent dephosphorylation of NFAT, resulting in less shuttling of NFAT 
into the nucleus. As well, CnA content was reduced in CsA treated adult animals compared to 
vehicle treated littermates, suggesting reduced CnA activity. However, in direct contrast to the 
immunofluorescence data, Western blotting analyses indicated a reduction in phosphorylated 
NFATc1 with no changes in total NFATc1 in response to CsA treatment. Those results imply 
that CsA treatment actually increased CnA activity resulting in increased nuclear NFAT.  
However, that is very unlikely since increased CnA signaling would be expected to promote type 
I fibre gene expression and here, the percentage of fibres expressing MHCI was reduced 
following CsA treatment which corresponds better with the immunofluorescence data showing 
reduced nuclear NFAT, at least in 4-6 month old mice.  Further complicating the interpretation 
of these results is the fact that CsA treatment in 4-6 week old animals resulted in decreased type I 
fibre percentage but CnA signaling as indicated by immunofluorescence analysis of nuclear 
NFAT, was not different compared with vehicle.  Taken together, the results suggest that CsA 
treatment was successful at blunting CnA activity in the soleus, and probably more so in 4-6 
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month old animals than 4-6 week old animals, but this conclusion is less convincing given the 
discrepancy in results noted above. 
 There are several factors that could contribute to the discrepancy in the measures of CnA 
signaling such as the role of other NFAT isoforms and the phosphorylation and nuclear export of 
NFAT. As mentioned previously, there are five members of the NFAT protein family. NFATc1-
4 are activated through the Ca2+/calcineurin pathway while NFAT5, the primordial isoform, is 
activated by osmotic stress (95). Although there is some redundancy in function, the four Ca2+ - 
dependent isoforms have been linked to differing downstream consequences. NFATc1 deletion 
substantially reduces cytokine production suggesting its importance in the innate immune 
response (96).  A developmental role for NFATc2 is presumed due to impaired myoblast fusion 
and regeneration post injury in NFATc2 null mice (78). NFATc3 has been found active in a 
transgenic mouse model of Parkinson's disease with increased cytosolic [Ca2+] in midbrain 
dopaminergic neurons (97). Deletion of two or more NFAT isoforms also has differing effects on 
phenotype. For instance, deletion of NFATc1 and NFATc2 results in effective loss of cytokine 
production in T-cells while deletion of NFATc3 and NFATc4 promotes defects in vascular 
developmental organization and results in embryonic death (98). This heterogeneity between 
specific NFAT isoforms is also present within skeletal muscle. Abbott et al. (1998) showed a 
clear pattern of expression during differentiation of cultured human skeletal muscle cells, with 
NFATc1, NFATc2, NFATc3 corresponding with myoblasts, nascent myotubes and mature 
myotubes, respectively (99). Correspondingly, differences in mice lacking specific NFAT 
isoforms have been witnessed such that mice lacking NFATc3 have a reduction in myofibre 
number while NFATc2 null mice show impaired muscular hypertrophy (78, 100). In respect to 
fibre type promotion, the NFAT-MHC isoform patterns are complex as well. Promotion of 
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neonatal MHC has been linked solely to NFATc2 while NFATc1 and NFATc3 preferentially 
bind to the promoter for embryonic MHC (101) Historically the expression of MHCI has been 
associated with NFATc1. Indeed, a constitutively active NFATc1 mutant stimulated the MHCI 
transcription while inhibiting the fast MHCIIb promoter (81). As well, a transgenic mouse line 
with skeletal muscle specific knockout of NFATc1, has shown decreased percentages of type I 
fibres compared to wild type littermate (102). In this thesis, assessment of NFATc1 was chosen 
because of its strong association with MHCI expression in the literature. However, Calabria et al. 
(2009) has demonstrated that this may not be such an exclusive relationship by inducing a 
knockdown of individual NFAT isoforms 1-4 and assessing the corresponding effect on DNA 
promoters for the differing adult MHC isoform (103). In their study, the MHCI promoter was 
blunted in all the NFAT isoform knockdowns, which indicates that the transcriptional regulation 
of MHCI by each isoform may not be redundant. This is an imperative piece of data for this 
thesis as NFATc1 may not be the sole isoform driving MHCI expression. Further assessment 
should be done on additional NFAT isoforms to confirm localization in order to truly show the 
link between the CsA treatment and the downstream fibre type variations.   
The rate at which NFAT is shuttled in and out of the nucleus is also necessary to consider 
for the understanding of the discrepancies in our data. As discussed previously, 
dephosphorylaton and nuclear import of NFAT isoforms occurs via CnA activation and has been 
reported to occur as quickly as 15 minutes after a sustained Ca2+ signal (104). Nuclear export of 
NFAT is also highly regulated and achieved by the phosphorylation and subsequent covering of 
nuclear localization signal. NFAT export can be achieved through several kinases, including 
glycogen synthase-3 kinase (GS3K) (105), casein kinase 1 (CK1) (106), protein kinase A (PKA) 
(107), MAP kinases p38 and JNK(108). As NFAT isoforms have upwards of 18 phosphorylation 
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sites dispersed throughout the regulatory region, the coordination and combination of these 
kinases is required for inactivation and nuclear export. The timing for nuclear export varies 
between different cells/tissues with rapid export in lymphocytes and prolonged nuclear 
localization of up to two hours in neurons (109, 110). The timing of both import and export have 
yet to be uncovered within skeletal muscle but are important to consider when interpreting the 
findings of this study. As sample preparation varies for Western blotting and 
immunofluorescence, a rapid shift in localization of NFAT from cytosol to nucleus and back 
may explain the differing results for NFAT localization with CsA treatment in PlnOE mice.  
Interestingly, the modest reduction in type I fibre predominance corresponded with a 
significant reduction in both monomer PLN and the ratio of monomer to pentamer PLN in the 4-
6 month old mice, further supporting the view that the CsA treatment was successful in blocking 
transcription of MHCI and the attached transgene for PLN in those mice. The decrease in 
monomer PLN content would be expected to correspond with an increase in SERCA activity due 
to less inhibition of SERCA by active, monomer PLN.  PLN has previously been shown to 
regulate rates of relaxation, with PLN ablation showing a marked increase in the rate (41) and 
overexpression of PLN causing greatly reduced rates of relaxation (50), As such, it was also 
hypothesized that rates of relaxation would be increased due to the reduction in monomer PLN, 
however there were no significant differences in rates of relaxation between treatment groups. 
Surprisingly. but consistent with the lack of difference in relaxation rates between groups, there 
were also no differences in SERCA activity between CsA and vehicle treated animals. The 
discrepancy between the reduction in PLN and its effect on SERCA activity and relaxation are 
surprising; however, PLN has been previously shown to dissociate from SERCA with high 
intracellular Ca2+ (111). As such, speculation on the inhibitory effects of PLN on SERCA activity 
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during the contraction-relaxation cycle cannot occur without further research into the co-
immunoprecipitation of SERCA and PLN in this model.  
With respect to other histological and functional markers of CNM, there was also a 
decrease in the presence of intracellular fibrosis indicating a milder CNM phenotype following 
CsA treatment, but only in 4-6 month old animals. Although it t is unclear as to whether this 
reduction in fibrosis is attributable to a generally improved phenotype or to the specific 
inhibition of CnA, as it has been shown to activate fibroblasts and collagen synthesis in cardiac 
muscle (91), it did corresponds with improved muscle function. Compared with vehicle, CsA 
treatment produced an improvement in soleus force per cross sectional area at both twitch and 
tetanic frequencies at 4-6 months of age.  In light of these findings, it seems CsA was successful 
in moderately improving both fibre type and muscle function within this model of CNM for 
animals aged 4-6 months.  
However, treatment with CsA did not affect the percentage of centrally located nuclei as 
was hypothesized. There was a main effect of age, with older 4-6 month animals displaying 
increased central nuclei across treatment groups. Although central nuclei are considered a 
negative disease characteristic in CNM, satellite cell proliferation and differentiation to 
regenerate myo-neuclei is also well documented within myopathies and injury wherein central 
nuclei are present (112). Future assessments into the colocalization of Pax7, a satellite cell 
marker, with centrally located nuclei should be done to determine whether there are more 
regenerating fibres with CsA treatment than vehicle treated animals. 
Corresponding with central nuclei, the persistence of dense SDH staining in the interior 
of the fibre was also observed in CsA treated animals. Unequal SDH staining between fibres is 
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also related to the muscle fibre type, with the darkest staining found in type IIA fibres, which are 
the most oxidative rodent fibre. As can be seen in Figure 5, a noticeable correlation exists 
between fibres with lighter SDH staining, corresponding with type I fibres, and the presence of 
central aggregation of SDH bodies. Previous studies have linked this abnormal SDH staining 
with significant decreases in cytochrome c oxidase activity and ATP levels in primary muscle 
cells from 4 X-linked CNM patients and in MTM1 KO mice (93). The persistence of this CNM 
feature in both age groups indicates that CsA was unsuccessful in reducing this abnormality. 
Together, both the central nuclei and SDH findings suggest that the origin of these CNM 
characteristics is not associated with the transcription of MHCI. Several cytoskeleton proteins 
have been uncovered in connection to cellular development and organelle organization but the 
mechanisms by which organelles, such as nuclei and mitochondria, navigate to their proper 
position is not fully understood. One such associated protein is DNM2. Both mice and humans 
with X-linked CNM show an upregulation of DNM2 and treatment to reduce DNM2 has been 
shown to improve intracellular organization within these tissues (113). The PlnOE CNM model 
also displays an overexpression of DNM2, which may be more responsible for the improper 
localization of nuclei and mitochondria than the CnA-NFAT pathway. As well, there is evidence 
to suggest that these histological features do not directly determine the severity of the disease as 
seen in the Chen et al (2014) review of DNM2-CNM where a patient with the highest central 
nuclei counts (93%) maintained the ability to self-ambulate much longer than other patients with 
lower central nuclei counts (114).  This corresponds with the findings of this thesis in that there 
were CsA treatment improvements in muscle contractility with no changes in some CNM 
features, namely central nuclei and central oxidative activity. 
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There was also nearly a 50% reduction in the expression of SLN in CsA treated verses 
vehicle treated 4-6 month old animals although this finding was statistically non-significant 
(p=0.1).  Nevertheless, this is an interesting finding as there is evidence to suggest it may have a 
positive or negative effect on phenotype. As mentioned previously, SLN and PLN together can 
bind to SERCA and cause super inhibition of the pump. As such, the findings in this thesis 
showing a reduction in both PLN and SLN should partially relieve this inhibition and alleviate 
some of the detrimental effects of chronically elevated Ca2+ thought to be involved in this CNM 
model. Conversely, unpublished data from our lab have shown that when SLN is ablated in this 
mouse model it worsens the myopathy, with SLN knockout-PlnOE (SKOPOE) animals exhibiting 
increased muscle atrophy, weakness, and a reduction in total muscle fibre count (115). 
Interestingly, the soleus muscles of these SKOPOE animals also presented reduced CnA activity 
and an inability for compensatory type II fibre hypertrophy. From the two models, PlnOE and 
SKOPOE, it can be seen that a bivariate relationship exists between CnA activity and SLN 
expression, in that CnA activity may regulate SLN expression and hypertrophy and SLN 
expression may be required for CnA activity and hypertrophy. Therefore the reduction in SLN 
witnessed with CsA treatment may be a result of reduced CnA activity. Whether this SLN 
reduction is detrimental to phenotype as with the SKOPOE mice or if it is a beneficial effect of 
CsA treatment in PlnOE mice that partly contributes to an improved overall muscle health and 
function is yet to be determined from this research.  
Finally, it was originally hypothesized this CsA treatment would be more effective in the 
younger, 4-6 week old animals as it would be more effective to block CnA activity before the 
full CNM phenotype was achieved. The results of this study do not support this hypothesis. 
Although the same CsA dose did significantly blunt the development of type I fibre type 
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predominance, many of the other improvements, such as improved force and decreased fibrosis 
were not evident in the younger animals. As reported by Fajardo et al. (2015), the CNM 
phenotype within this model is progressive reaching a severity plateau at 4-6 months of age (51). 
Many findings in this thesis correspond with this progression, including increased soleus to body 
weight ratios, increased twitch force, decreased fibrosis and decreased central nuclei counts in 
comparison to vehicle treated older animals. There was also a significantly lower colocalization 
of DAPI and NFAT in the both CsA and vehicle treated 4-6 week old animals compared to 
vehicle treated 4-6 month old mice, which suggests that the CnA-NFAT pathway is less 
activated at the younger age. Furthermore, as mentioned above, treatment efficacy may have 
been lower in the 4-6 week old animals since immunofluorescence measures of CnA signaling 
did not reveal any evidence that CsA blocked CnA activity at that age. Taken together the 
improvement of the myopathy may have been harder to detect with the milder CNM phenotype 
and reduced activation of CnA associated with 4-6 week old animals. Future studies may pursue 
administering a longer CsA treatment protocol and increasing the power of the assessment by 
adding additional animals or assessing the optimal age for treatment.  
 
NFAT proteins show activation, dephosphorylation and nuclear import, with low 
sustained Ca2+ plateaus but seem to be insensitive to more rapid, larger influxes of Ca2+ (116). 
Interestingly, this is a similar activation pattern seen with PLN, wherein PLN is bound to 
SERCA at chronic, low Ca2+ levels and disassociates from the pump upon higher Ca2+ transients. 
Theoretically these findings would suggest that in a model with such prolific PLN 
overexpression, CnA activation may be attributable to PLNs interaction with SERCA as the 
delay in uptake of Ca2+ into the SR could be sufficient to initiate the formation of the Ca2+-
calmodulin complex.  That being said, one of the major limitations in this study and previous 
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research done using this PlnOE mouse model for CNM is the lack of a direct measure of 
intracellular Ca2+ concentrations. It is assumed the overexpression of PLN, and corresponding 
inhibition of SERCA, has increased intracellular [Ca2+] but we and others have not directly 
measured cytosolic Ca2+ in intact muscles. Although difficult to do, measurement of intracellular 
[Ca2+] in vivo is possible. Intracellular Ca2+ has been quantified using the Ca2+-fluorescent dye, 
Indo-1, to assess both resting Ca2+ levels and Ca2+ dynamics during depolarization of 
enzymatically isolated single muscle fibres from mdx-/- animals (117). That being said the 
dystrophic phenotype witnessed in mdx-/- mice presents a less severe myopathy than the PlnOE 
model of CNM and the single fibre dissections may prove to be problematic.  Success in 
quantifying intracellular Ca2+ would help to define whether Ca2+ dysregulation is responsible for 
the CNM phenotype and, if so, it would help gauge the ability of treatments in targeting Ca2+ and 
its associated pathways.  
Finally, although extensively discussed in relation to fibre type in this thesis, CnA and 
NFAT are also responsible for activation of the innate immune response. Congruent with this, 
CsA treatment is widely used in immunosuppression in humans and has been shown to reduce 
the activation of many diverse immune cell types (76, 118-121). Therefore, treatment of PlnOE 
animals with the relatively high dose of CsA used in this study would effectively suppress any 
immune system response. This immunosuppression should be noted with respect to the side 
effects it would cause for patients. This thesis may give merit to the concept of fibre type 
targeting as a potential treatment strategy, however the immune suppression associated with CsA 
treatment is substantial and may limit its clinical use for treatment of CNM in humans.    
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Future Directions and Conclusion 
 
Moving forward, I believe there are still many potential avenues to target PLN as a 
therapeutic target for CNM; however, it is first necessary to truly uncover the connection 
between this SERCA-regulatory protein and CNM. Two main theories present themselves when 
trying to uncover the mechanism in which the overexpression of PLN causes CNM. The first is 
tied to the regulatory role of PLN and its effects on Ca2+ levels. In theory, the overexpression of 
PLN, and the subsequent reduction in SERCA activity, would result in high intracellular [Ca2+]. 
This elevated cytosolic [Ca2+], has been linked to several detrimental downstream effects such as 
central nuclei, increased protein degradation, calpain activation, and mitochondrial swelling and 
rupture (29, 122, 123). Several features of this CNM model support this theory, including 
increased calpain activity, the predominance of MHCI and irregularities in SDH staining 
suggesting unusual mitochondrial function and localization in PlnOE vs WT animals (51). This 
theory may prove relatively easy to assess through a variety of means such as intracellular Ca2+ 
measurement in vivo or the manipulation of Ca2+ buffering proteins such as parvalbumin (PV). 
Theoretically, increasing PV content in PlnOE muscles would bind to and buffer excess cytosolic 
Ca2+ and any improvements in the CNM phenotype could then be attributed to improved Ca2+ 
homeostasis with this model.  
 The second theory that may explain the connection between PLN and a CNM phenotype 
is the localization of PLN within cellular membranes. Although PLN is classically thought to 
reside only in the SR membrane, cumulating evidence has found it in other cellular membranes. 
When assessing PLN in differentiating myocytes, Stenoien et al. (2007), found the localization of 
PLN varied throughout differentiation with PLN being present in vesicles and then trafficked to 
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the plasma membrane for degradation in myoblasts that had yet to fully form SR (124). A human 
mutation in PLN has caused its localization to the plasma membrane in cardiomyocytes where it 
interacts with the N+-K+ ATPase pump (125). As well, very recent findings from Chiou et al. 
(2016), show localization of PLN to the nuclear envelope of mature cardiomyocytes and suggest 
a role for PLN in nuclear Ca2+ dynamics (126). Although entirely speculative, an overexpression 
of PLN may promote its localization to other cellular membranes and/or vesicles, which may 
disrupt normal membrane dynamics within muscle fibres.  Interestingly, autophagy, a cell 
degradation process in which a double membrane vesicle, or autophagosome, engulfs a target 
organelle or protein aggregate for degradation, was shown to be the primary mode for PLN 
degradation in cardiomyocytes (127, 128). Disrupted autophagy has already been linked to CNM 
by increased levels of a phosphatase known to initiate autophagy, PtdIns(3)P, and markers for 
autophagosome membrane development, LC3-I and LC3-II, along with elevation of the 
lysosomal marker, Lamp2, implicating a late stage halt in the autophagy process within MTM1 
mice (129). Tempered autophagy in response to starvation was also found in mice with DNM2 
mutations, which corresponds with the autosomal dominant form of CNM (130), which is the 
form modeled by PlnOE mice.  In relation to the PlnOE CNM model, Fajardo et al, found an 
increase in LC3II as well as a trending increase in the ratio of LC3II to LC3I, in C57 black 
animals harbouring the same plnOE transgene, suggesting alterations in the autophagy process 
within this model as well (51). Together the above data give credence to a mechanism for PLN to 
cause a CNM phenotype via disruption in regulation of basal autophagy levels.  
Furthermore, membrane dysfunction is indicated through notable abnormalities in 
dystrophin staining upon immunofluorescence imaging of muscles from differing mouse 
backgrounds overexpressing PLN. Normally, dystrophin is associated with the sarcolemmal 
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membrane surrounding muscle fibres, but as can be seen in Fig. 11, dystrophin was found within 
several muscle fibres either alone or surrounding central nuclei. The process by which this 
dystrophin is incorrectly localized is not known but is assumed not to be non-specific binding as 
the pattern of expression is seen across mouse strains and experiments. In conjunction with the 
above evidence, nearly all of the genetic mutations associated with human cases of CNM are 
associated with a disruption in membrane trafficking, and as such this theory deserves serious 
review. Future studies could assess PLN localization through immunofluorescence or western 
blotting of cellular fractions. Future research focused on more clearly defining this process by 
which increased PLN causes CNM in this model is clearly necessary as it may lead to a strategy 
to address the increase in PLN expression in human patients with CNM. 
 
 
While the mechanism driving the CNM phenotype in PlnOE mice is currently unknown, 
the increase in PLN content within biopsies from human patients with CNM shows this 
relationship is not confined to murine muscle.  As such, future studies could also evaluate the 
Figure 11. Dystrophin Abnormalities in various Immunofluorescence of PlnOE animals. 
Immunofluorescence for NFAT, DAPI and Dystrophin from PlnOE animals on an FVB-n strain of mice 
and Immunofluorescence for MHCI, MHCIIa and Dystrophin from PlnOE animals on a C57 mouse. As 
denoted by the white arrows both strains and experiments show central localization of dystrophin 
within muscle fibres.  
FVB-n  C57  
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merit of treatments, which more directly target PLN in patients. As Ca2+ dysregulation is 
associated with detrimental myopathic features, and PLN exacerbates this by inhibiting SERCA 
function and delaying SR Ca2+ uptake, targeting PLN directly may prove more fruitful than 
targeting downstream pathways as in this thesis. A potential treatment, which would directly 
inhibit PLN and improve SERCA function is via B-agonist administration through activation of 
PKA and consequent phosphorylation of PLN. Phosphorylation of PLN, shown to weaken its 
inhibition of SERCA2a (44), has been used as a strategy in cardiac muscle, increasing the 
apparent Ca2+ affinity and enhancing relaxation during 𝛽-adrenergic stimulation (45, 46).   
Further research into the CnA- NFAT pathway and its role within CNM is also required. 
To our knowledge, this is the first study to provide evidence that CnA is over-activated and 
NFAT may be localized within the nucleus within any model for CNM. We have previously 
shown that the activation of CnA and localization of NFAT varies between tissues in PlnOE mice 
compared to WT, as nuclear NFAT was significantly increased in gluteus minimus, a trending 
increase was found in soleus and no difference was seen in diaphragm muscles (84).  As such, 
treatment with CsA may be more effective in one tissue over another. Although this thesis 
focused on the soleus muscle, preliminary data seen in Fig. 12, suggest that this treatment may 
have had more of an effect on other postural muscles as noted by the drastic reduction in PLN 
within CsA-treated gluteus minimus muscles. Exploring the role of the CnA-NFAT pathway 
within different muscle groups and between models may provide additional insight into its 
effectiveness as a target for therapeutic strategy.  
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 As the exact mechanisms driving the differing CNM classifications are still being 
uncovered, there has yet to be any form of treatment for CNM patients outside of physiotherapy. 
This study provides evidence that CsA treatment induces modest yet significant benefits as a 
treatment for CNM in PlnOE mice, including increased muscle function, decreased intracellular 
fibrosis and a mild restoration of fibre type distribution. Targeting fibre type as a potential 
treatment is both a novel concept and has merit as a universal treatment for CNM patients as the 
predominance of diseased type I fibres is a phenotype characteristic common to all 
classifications of CNM. Although this study does not provide enough evidence to suggest that 
CsA treatment should be examined in human CNM patients, it does provide merit and proof of 
concept for the targeting of fibre type as a potential avenue for therapeutic strategy. 
  
0.00
0.05
0.10
0.15
O
pt
ic
al
 D
en
si
ty
 (A
U
)
Vehicle
CsA Treated
PLN -
Ponceau -
Monomer PLN in CsA and Veh Treated Gluteus Minimum
Veh Veh VehCsA CsA
Figure	  12.	  CsA	  treatment	  on	  PLN	  expression	  in	  Gluteus	  Minimus	  of	  PlnOE	  animals.	  Quantification	  and	  full	  membrane	  image	  of	  the	  comparison	  of	  monomer	  PLN	  in	  gluteus	  minimus	  muscle	  of	  4-­‐6	  month	  of	  PlnOE	  animals	  treated	  with	  CsA	  or	  vehicle.	  	  Monomer	  PLN	  was	  normalized	  to	  total	  protein	  via	  ponceau	  stain.	  Statistical	  significance	  was	  not	  found	  due	  to	  the	  low	  power	  (n	  =	  3	  vs	  2)	  and	  the	  variance	  in	  vehicle	  treated	  samples.	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 Appendix 
Genotyping Protocol 
All PlnOE mice were ear notched and tagged at 3-4 weeks of age. The DNA was then extracted 
from ear notches samples using a pureLink Genomic DNA mini kit (Invitrogen, Carslbad, CA). 
PCR was performed on these DNA samples to amplify the DNA of interest. Briefly, 
approximately 50 ng of DNA was added to a Taq DNA polymerase mix (EP0402, Thermo 
Scientific Fermentas, Canada) containing Taq Buffer with (NH4)2S04 buffer (diluted to 1X), 4 
mM MgCl2, 200 μM dNTP (R0192, Thermo Scientific Fermetas), 0.625 units of Taq DNA 
polymerase, and 0.4 μM of the appropriate forward and reverse primers (listed below). Samples 
were then placed in a thermal cycler (MJ MINI, Bio- Rad Canada) and underwent their 
respective PCR reactions (protocol below). The amplified products were then separated on a 1% 
agarose gel (in 1X TBE) containing 0.01% ethidium bromide (Bioshop, Canada) for 40 min at 
80V in 1xTBE buffer, and identified using a bio- imaging system (Syngene, Frederick, MD). 
 
Forward PlnOE primer, SK-1   5’-AAG GGG CGG GAA GGC ATA TAG-3’ 
Reverse PlnOE primer, PLB-RC  5’-GAT TCT GAC GTG CTT GCT GAGG-3’ 
 
PlnOE PCR Protocol  
1. Denaturation @95°C for 3min 
2. Denaturation @94°C for 30sec 
3. Annealing @70°C for 30sec 
4. Extension @72°C for 1 min 
 *Repeat Steps 2-4 for 34 cycles 
5. Final Extension  @72°C for 10min 
6. Hold @4°C until electrophoresis  
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NFAT Immunofluorescence Protocol  
1. Remove slides and air dry for 5 mins 
2. Pat Pen around sections 
3. Incubate in 4% paraformaldehyde (make fresh: 25ml dH2O + 3ml formaldehyde) on 
shaker for 10 min at RT.  
4. Wash 3 times for 5 min in PBS in Columbia jar while on shaker (approx 220 rpm). Blot 
excess.  
5. Permeablize with 0.5% Triton X-100 solution for 30 min at RT on shaker. Blot excess.  
6. Wash 3 times for 5 min in PBS in Columbia jar while on shaker (approx 220 rpm). Blot 
excess. 
7. block in 5% Goat Serum-PBS for 1 hour at room temperature.  
8.  Primary at a dilution of 1:50 overnight at 4°C in a humidified chamber.  
a. Add Dystrophin 1:100 
9. Wash extensively with PBS 3 times 5 min in Columbia jar while on shaker. 
10. Secondary fluorescent IgG1 antibody 1: 500 for 1hr at RT 
a. Dystrophin secondary 1:500 IgG2a 
****If nuclear counterstaining is needed proceed as follows: 
a. While sections are washing make up DAPI stain. Protected from light by 
wrapping in foil.   
b. To make DAPI: dilute 10μl of 30μM working solution to 990μl PBS. Keep 
new diluted solution wrapped in foil until needed. 
c. Incubate sections in DAPI stain for 2 min while in the dark. Use 100uL of the 
diluted solution per slide/group of sections.   
d. Wash 3 times for 5 min in dark on shaker in new PBS. 
11. Blot excess. Add 15uL of Prolong to each slide/group of sections and cover with a #1 
coverslip. These coverslips are very thin; if two are stuck together a “hologram” will be 
seen in their surfaces.  
12. Carefully cover edges of coverslip with clear nail polish, and allow to dry in the dark for 
5-10 minutes. 
 
 
Primary Info 
Catalog number: MA3-024  
Company: ThermoFisher 
Class: monoclonal 
Host: Mouse 
Isotype: IgG1 
IF concentration: 1:10-100 
IHC concentration: 1:20-200 
Western blot: 1:2000 
Secondary Info 
IgG1  
 
Counter Stain  
DAPI – nuclei 
Dystrophin (primary 1:100, secondary 
1:500 IgG2a) 
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Western Blotting Protocols 
 
Target 
Protein 
Antibody 
Info 
Total 
Protein 
Load  
Run Primary Secondary Detection 
PLN 
 
Pierce 
Antibodies 
MA3-922 
Monoclonal 
Mouse 
2.5ug 75 mins 
@100V 
1:2000 
signal 
enhancer 1hr 
at  RT 
1:2000 anti-
mouse 
ECL 30 sec 
exposure 
CnA 
 
Sigma Aldrich 
C1956 
Monoclonal 
Mouse 
10ug 15mins 
@120V,60 
mins 
@100V 
1:1000 
5%milk in 
TBST 
overnight 
4°C 
1:2000  Femto 30 
sec exposure 
NFAT-p  
 
Pierce 
Antibodies 
PA5-38301 
Polyclonal 
Rabbit 
20ug 15mins 
@120V,60 
mins 
@100V 
1:2000 
5%milk  
overnight at 
4°C in TBST 
1:2000 Luminata 
1 min 
exposure 
NFAT 
 
Pierce 
Antibodies 
MA3-024 
Monoclonal 
Mouse 
Strip and reprobe 
NFAT-p membrane 
1:2000 
signal 
enhancer 
overnight 
4°C 
1:2000 Luminata 
1 min 
exposure 
SLN 
 
Lampire 
Biological 
Laboratories 
Proprietary 
Polyclonal 
Rabbit 
20ug 75 mins 
@100V 
1:100 
3%BSA and 
TBST 
overnight 
4°C 
1:2000 anti-
rabbit 
Luminata 
1 min 
exposure 
Actin 
 
Sigma Aldrich 
A2066 
Polyclonal 
Rabbit 
Strip and reprobe from 
different membrane 
1:10000 
5%milk in 
TBST 1hr at 
RT 
1:2000 ECL 10 sec 
exposure 
